Mise Yoshihiro, Aloia Thomas A, Brudvik Kristoffer W, Schwarz Lilian, Vauthey Jean-Nicolas, Conrad Claudius
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ann Surg. 2016 Jan;263(1):146-52. doi: 10.1097/SLA.0000000000001194.
To investigate prognostic impact of parenchymal-sparing hepatectomy (PSH) for solitary small colorectal liver metastasis (CLM).
It is unclear whether PSH confers an oncologic benefit through increased salvageability or is a detriment through increasing recurrence rate.
Database of 300 CLM patients with a solitary tumor (≤ 30 mm in size) was reviewed from 1993 to 2013. A total of 156 patients underwent PSH and 144 patients underwent right hepatectomy, left hepatectomy, or left lateral sectionectomy (non-PSH group).
The rate of PSH increased over the study period (P < 0.01). PSH did not impact negatively on overall (OS), recurrence-free, and liver-only recurrence-free survival, compared with non-PSH (P = 0.53, P = 0.97, and P = 0.69, respectively). Liver-only recurrence was observed in 22 patients (14%) in the PSH and 25 (17%) in the non-PSH group (P = 0.44). Repeat hepatectomy was more frequently performed in the PSH group (68% vs 24%, P < 0.01). Subanalysis of patients with liver-only recurrence revealed better 5-year overall survival from initial hepatectomy and from liver recurrence in the PSH than in the non-PSH group [72.4% vs 47.2% (P = 0.047) and 73.6% vs 30.1% (P = 0.018), respectively]. Multivariate analysis revealed that non-PSH was a risk of noncandidacy for repeat hepatectomy (hazard ratio: 8.18, confidence interval: 1.89-45.7, P < 0.01).
PSH did not increase recurrence in the liver remnant but more importantly improved 5-year survival in case of recurrence (salvageability). PSH should be the standard approach to CLM to allow for salvage surgery in case of liver recurrence.
探讨保留肝实质肝切除术(PSH)对孤立性小的结直肠癌肝转移(CLM)患者预后的影响。
PSH是通过提高挽救性而带来肿瘤学获益,还是会因增加复发率而产生不利影响尚不清楚。
回顾1993年至2013年300例患有孤立性肿瘤(大小≤30mm)的CLM患者的数据库。共有156例患者接受了PSH,144例患者接受了右肝切除术、左肝切除术或左外叶切除术(非PSH组)。
在研究期间,PSH的比例有所增加(P<0.01)。与非PSH组相比,PSH对总生存期(OS)、无复发生存期和仅肝脏无复发生存期均无负面影响(分别为P=0.53、P=0.97和P=0.69)。PSH组有22例患者(14%)出现仅肝脏复发,非PSH组有25例患者(17%)出现仅肝脏复发(P=0.44)。PSH组更频繁地进行再次肝切除术(68%对24%,P<0.01)。对仅肝脏复发患者的亚组分析显示,PSH组从初次肝切除和肝脏复发后的5年总生存期均优于非PSH组[分别为72.4%对47.2%(P=0.047)和73.6%对30.1%(P=0.018)]。多因素分析显示,非PSH是再次肝切除术非合适候选的风险因素(风险比:8.18,置信区间:1.89-45.7,P<0.01)。
PSH不会增加肝残余组织的复发,但更重要的是在复发情况下(挽救性)可提高5年生存率。PSH应成为CLM的标准治疗方法,以便在肝脏复发时能够进行挽救性手术。